HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat

Journal of Pathology: Clinical Research

Volumn 2, Issue 2, 2016, Pages 59-71

  Angelika Ihle, Michaela ^a   Merkelbach Bruse, Sabine ^a   Hartmann, Wolfgang ^a,b   Bauer, Sebastian ^c   Ratner, Nancy ^d   Sonobe, Hiroshi ^e   Nishio, Jun ^f   Larsson, Olle ^g   Åman, Pierre ^h   Pedeutour, Florence ⁱ   Taguchi, Takahiro ^j   Wardelmann, Eva ^a,b   Buettner, Reinhard ^a   Schildhaus, Hans Ulrich ^a,k  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e CHUGOKU CENTRAL HOSPITAL   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^j KOCHI UNIVERSITY   (Japan)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

Biomarker; GIST; HDACi; HR23b; RAD23b; Sarcoma

Indexed keywords

BELINOSTAT; BIOLOGICAL MARKER; ENTINOSTAT; MOCETINOSTAT; PROTEIN HR23B; UNCLASSIFIED DRUG; VORINOSTAT;

ANGIOSARCOMA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SARCOMA CELL LINE; SYNOVIAL SARCOMA; WESTERN BLOTTING;

EID: 84971198009     PISSN: None     EISSN: 20564538     Source Type: Journal    
DOI: 10.1002/cjp2.35     Document Type: Article

References (47)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
2. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006;79:259-270.
3. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-3588.
4. Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 2010;46:1573-1579.
5. Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008;81:170-176.
6. Thompson CA. Belinostat approved for use in treating rare lymphoma. Am J Health Syst Pharm 2014;71:1328.
7. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 2011;20:823-829.
8. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-1228.
9. US National Institutes of Health Clinical Trials. U.S. National Institutes of Health; Available from: www.clinicaltrials.gov September, 2015.
10. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
11. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238-243.
12. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21.
13. Fotheringham S, Epping MT, Stimson L, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009;15:57-66.
14. Sugasawa K, Ng JM, Masutani C, et al. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol Cell Biol 1997;17:6924-6931.
15. Petruseva IO, Evdokimov AN, Lavrik OI. Molecular mechanism of global genome nucleotide excision repair. Acta Naturae 2014;6:23-34.
16. Elsasser S, Chandler-Militello D, Muller B, Hanna J, Finley D. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J Biol Chem 2004;279:26817-26822.
17. Kim B, Ryu KS, Kim HJ, Cho SJ, Choi BS. Solution structure and backbone dynamics of the XPC-binding domain of the human DNA repair protein hHR23B. FEBS J 2005;272:2467-2476.
18. Liang RY, Chen L, Ko BT, et al. Rad23 interaction with the proteasome is regulated by phosphorylation of its ubiquitin-like (UbL) domain. J Mol Biol 2014;426:4049-4060.
19. Yeo W, Chung HC, Chan SL, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012;30:3361-3367.
20. Khan O, Fotheringham S, Wood V, et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010;107:6532-6537.
21. Cassier PA, Lefranc A, Amela EY, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer 2013;109:909-914.
22. Chu QS, Nielsen TO, Alcindor T, et al. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200dagger. Ann Oncol 2015;26:973-981.
23. Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol 2010;21(Suppl 7):vii265- vii269.
24. Stratford EW, Castro R, Daffinrud J, et al. Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma 2012;2012:148614.
25. Dejligbjerg M, Grauslund M, Christensen IJ, et al. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 2008;4:101-109.
26. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497.
27. Busam KJ, Fletcher CD. The clinical role of molecular genetics in soft tissue tumor pathology. Cancer Metastasis Rev 1997;16:207-227.
28. Yamamoto S, Tanaka K, Sakimura R, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 2008;28:1585-1591.
29. Muhlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009;69:6941-6950.
30. Liu S, Cheng H, Kwan W, Lubieniecka JM, Nielsen TO. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther 2008;7:1751-1761.
31. Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21:333-347.
32. Hrzenjak A, Moinfar F, Kremser ML, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 2010;9:49.
33. Heinicke U, Fulda S. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Lett 2014;351:50-58.
34. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7:583-598.
35. Wozniak MB, Villuendas R, Bischoff JR, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010;95:613-621.
36. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008;216:495-504.
37. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010;10:462-470.
38. Tula-Sanchez AA, Havas AP, Alonge PJ, et al. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: role of cyclin-dependent kinase inhibitors. Cancer Biol Ther 2013;14:949-961.
39. Larsson DE, Lovborg H, Rickardson L, Larsson R, Oberg K, Granberg D. Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res 2006;26:4125-4129.
40. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589.
41. New M, Olzscha H, Liu G, et al. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ 2013;20:1306-1316.
42. Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. J Hematol Oncol 2013;6:69.
43. Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30:2248-2255.
44. Olofsson A, Willen H, Goransson M, et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 2004;25:1349-1355.
45. Kabjorn Gustafsson C, Stahlberg A, Engtrom K, Danielsson A, Turesson I, Aman P. Cell senescence in myxoid/round cell liposarcoma. Sarcoma 2014;2014:208786.
46. Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30-41.
47. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.